# Prostate Cancer * **Definition:** A form of cancer that occurs in the prostate, a small walnut-shaped gland that produces seminal fluid in men, characterized by the uncontrolled growth of cells in the prostate gland and is one of the most common cancers among men worldwide. * **Taxonomy:** Healthcare Topics / Prostate Cancer ## News * Selected news on the topic of **Prostate Cancer**, for healthcare technology leaders * 12.4K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/12/2025 | [**Novel analysis identifies markers that may predict failure of metastatic prostate cancer treatment**](https://medicalxpress.com/news/2025-05-analysis-markers-failure-metastatic-prostate.html) | [[MedicalXpress]] | | 5/11/2025 | [**After Prostate Cancer, Physical Activity Revives Erections**](https://www.medscape.com/viewarticle/after-prostate-cancer-physical-activity-revives-erections-2025a1000be2) | [[Medscape]] | | 5/1/2025 | [**New prostate cancer test pinpoints disease better than PSA option, study finds - AOL.com**](https://www.aol.com/prostate-cancer-test-pinpoints-disease-090003355.html) | [[AOL]] | | 4/26/2025 | [**TikTok, social media does more harm than good for prostate cancer education**](https://www.urologytimes.com/view/tiktok-social-media-does-more-harm-than-good-for-prostate-cancer-education) | [[Urology Times]] | | 4/22/2025 | [**UQ plays key role in a national effort to revolutionize prostate cancer treatment**](https://www.news-medical.net/news/20250422/UQ-plays-key-role-in-a-national-effort-to-revolutionize-prostate-cancer-treatment.aspx) | [[News Medical Net]] | | 4/18/2025 | [**Can a Polygenic Risk Score Turn the Tide on Prostate Cancer Screening?**](https://www.medscape.com/viewarticle/can-polygenic-risk-score-turn-tide-prostate-cancer-screening-2025a100098k) | [[Medscape]] | | 3/27/2025 | [**TBX2 protein acts as a switch to drive prostate cancer treatment resistance, study finds**](https://medicalxpress.com/news/2025-03-tbx2-protein-prostate-cancer-treatment.html) | [[MedicalXpress]] | | 3/27/2025 | [**Going to screenings may lower death risk from prostate cancer by 23 AOL.com**](https://www.aol.com/going-screenings-may-lower-death-143925429.html) | [[AOL]] | | 3/24/2025 | [**ZERO Prostate Cancer Applauds Virginia's Landmark Decision to Ensure Prostate Cancer Screening at No Cost**](https://www.prnewswire.com/news-releases/zero-prostate-cancer-applauds-virginias-landmark-decision-to-ensure-prostate-cancer-screening-at-no-cost-302409496.html) | [[PR Newswire]] | | 3/24/2025 | [**ZERO Prostate Cancer Applauds Virginia's Landmark Decision to Ensure ... - Yahoo Finance**](https://finance.yahoo.com/news/zero-prostate-cancer-applauds-virginias-165900197.html) | [[Yahoo Finance]] | | 3/4/2025 | [**Study finds new potential for prostate cancer immunotherapy**](https://medicalxpress.com/news/2025-03-potential-prostate-cancer-immunotherapy.html) | [[MedicalXpress]] | | 3/4/2025 | [**Study finds new potential for prostate cancer immunotherapy - Medical Xpress**](https://medicalxpress.com/news/2025-03-potential-prostate-cancer-immunotherapy.html?deviceType=desktop) | [[MedicalXpress]] | | 2/25/2025 | [**Research highlights wide variation in prostate cancer testing between GP practices**](https://medicalxpress.com/news/2025-02-highlights-wide-variation-prostate-cancer.html) | [[MedicalXpress]] | | 2/19/2025 | [**Diet Changes Show Promise in Early Prostate Cancer**](https://www.medscape.com/viewarticle/diet-changes-show-promise-early-prostate-cancer-2025a10004gr) | [[Medscape]] | | 2/18/2025 | [**ZERO Prostate Cancer Launches Bold $20 Million 'Blitz The Barriers' Initiative to Close Gaps ...**](https://www.prnewswire.com/news-releases/zero-prostate-cancer-launches-bold-20-million-blitz-the-barriers-initiative-to-close-gaps-in-prostate-cancer-survival-in-highest-risk-communities-302378490.html) | [[PR Newswire]] | | 1/16/2025 | [**Accord BioPharma, Inc. Recognizes Milestone as More Than 10,000 Patients Gain Access ...**](https://www.prnewswire.com/news-releases/accord-biopharma-inc-recognizes-milestone-as-more-than-10-000-patients-gain-access-to-camcevi-leuprolide-302352332.html) | [[PR Newswire]] | | 12/19/2024 | [**Prostate Cancer Diagnosis and Therapy Market Size And Forecast: Key Segments and ...**](https://www.linkedin.com/pulse/prostate-cancer-diagnosis-therapy-market-size-forecast-key-rrpae) | [[Linkedin]] | | 11/4/2024 | [**Japan Prostate Cancer Therapy Market Valuation to Go Beyond US$ 2964.99 Million By 2032**](https://finance.yahoo.com/news/japan-prostate-cancer-therapy-market-123000958.html) | [[Yahoo Finance]] | | 9/25/2024 | [**Global Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR of ~12y 2030 - DelveInsight**](https://www.prnewswire.com/news-releases/global-prostate-cancer-diagnostics-market-to-observe-stunning-growth-at-a-cagr-of-12-by-2030--delveinsight-302258082.html) | [[PR Newswire]] | | 9/11/2024 | [**Addressing the Prostate Cancer Health Disparity in Black Men - HealthLeaders Media**](https://www.healthleadersmedia.com/cmo/addressing-prostate-cancer-health-disparity-black-men) | [[HealthLeaders Media]] | | 9/10/2024 | [**The National Civil Rights Museum Hosts Catalyst for Change Panel on Prostate Cancer ...**](https://finance.yahoo.com/news/national-civil-rights-museum-hosts-202200197.html) | [[Yahoo Finance]] | | 9/2/2024 | [**Urology Care Foundation Encourages Proactive Steps for Prostate Health This September**](https://markets.businessinsider.com/news/stocks/urology-care-foundation-encourages-proactive-steps-for-prostate-health-this-september-1033741304) | [[Business Insider Markets]] | | 7/31/2024 | [**Prostate Cancer Nuclear Medicine Diagnostics Global Market 2024 To Reach $1.49 Billion ...**](https://tech.einnews.com/amp/pr_news/731805151/prostate-cancer-nuclear-medicine-diagnostics-global-market-2024-to-reach-1-49-billion-by-2028-at-rate-of-14-8) | tech.einnews.com | | 7/10/2024 | [**Metastatic Prostate Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies - DelveInsight**](https://www.globenewswire.com/news-release/2024/07/10/2911351/0/en/Metastatic-Prostate-Cancer-Clinical-Trial-Pipeline-Insights-Featuring-75-Companies-DelveInsight.html) | [[Globe Newswire]] | | 6/18/2024 | [**PROSTATE CANCER FOUNDATION HIGHLIGHTS EVIDENCE-BASED PROSTATE CANCER SCREENING GUIDELINES FOR BLACK MEN**](https://www.prnewswire.com/news-releases/prostate-cancer-foundation-highlights-evidence-based-prostate-cancer-screening-guidelines-for-black-men-302174842.html) | [[PR Newswire]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **ZERO Prostate Cancer**: A leading organization advocating for prostate cancer awareness and support, focusing on eliminating barriers to early detection and ensuring equitable access to care. - **Prostate Cancer Foundation (PCF)**: An organization focused on funding research and providing guidelines for prostate cancer screening and treatment, particularly addressing health disparities. - **Moffitt Cancer Center**: Conducted a review on genomic tests for early-stage prostate cancer treatment decisions. - **Prostate Health Education Network (PHEN)**: An organization dedicated to improving prostate cancer outcomes, particularly among Black men, through awareness and clinical trial participation. - **Johns Hopkins Kimmel Cancer Center**: Research center studying the MYC gene's role in prostate cancer progression. - **Weill Cornell Medicine**: Research institution developing preclinical models to understand metastatic behavior in prostate cancer. - **Movember Foundation**: An organization focused on raising awareness and funds for men's health issues, including prostate cancer. - **Yale Urology**: Conducted significant research on genomic classifiers for prostate cancer risk assessment. - **AdMeTech Foundation**: An organization focused on improving patient care and reducing health disparities in prostate cancer through initiatives like the Prostate Cancer Resource Project. - **Broad Clinical Labs (BCL)**: A laboratory involved in genetic risk assessment for prostate cancer through the ProGRESS study. - **ZERO**: A non-profit organization focused on prostate cancer advocacy, education, and support, pushing for increased funding and awareness. - **Keck Medicine of USC**: Involved in a clinical trial assessing a steam-based treatment for prostate cancer. - **Human Longevity, Inc.**: A company dedicated to cancer prevention and patient care, offering financial support for members diagnosed with late-stage prostate cancer. - **Cedars-Sinai Cancer**: Research institution that published a study highlighting prostate cancer risks in transgender women on hormone therapy. - **Outcomes4Me Inc.**: A personalized cancer navigation platform that integrates NCCN Clinical Practice Guidelines for Prostate Cancer. - **Pfizer**: A pharmaceutical company involved in addressing health disparities in prostate cancer, particularly among Black men. ### Partnerships and Collaborations - **Prostate Cancer UK and The University of Manchester**: Advocating for changes in NHS guidelines to improve early diagnosis and address health inequalities in prostate cancer. - **ZERO Prostate Cancer and Local Organizations**: Collaborations aimed at education, outreach, and screening to improve access to care in high-risk communities. - **Prostate Health Education Network (PHEN)**: Hosting events to address racial disparities in prostate cancer among African American men. - **Men of African Descent and Carcinoma of the Prostate Consortium (MADCaP)**: A collaborative research initiative focusing on genetic risk factors for prostate cancer in African populations. - **Accord BioPharma and ZERO Prostate Cancer**: Collaboration to educate and empower men about prostate cancer and encourage screening. - **Cleveland Diagnostics and ZERO Prostate Cancer**: Collaborating on the 'A PSA on PSA' campaign to raise awareness and funds for prostate cancer research. - **Quest Diagnostics and Envision Sciences**: Collaboration to develop biomarker-based diagnostic tests for prostate cancer. - **NCCN and Pfizer**: Collaboration to advance research on hematologic toxicity associated with PARP inhibitors in prostate cancer treatment. - **Barbara Ann Karmanos Cancer Institute**: Collaborated with the Detroit Tigers and McLaren Health Care for the Prostate Cancer Awareness Night to promote prostate health. - **BCL and G2V**: Partnership to launch the ProGRESS study, focusing on genomic risk assessment for prostate cancer in veterans. - **National Civil Rights Museum and Pfizer**: Collaborating to host an event focused on tackling prostate cancer disparities in Black men. - **AdvanCell and University of Queensland**: A partnership aimed at developing targeted alpha therapies for prostate cancer, supported by $18 million from the Medical Research Future Fund. - **MDxHealth and University of Oxford**: Research collaboration to study the correlation between genomic testing and prostate cancer progression. - **UCLA-VA Collaborative Team**: Analyzed genomic alterations in veterans with metastatic prostate cancer to identify racial disparities in treatment responses. - **Indiana University and industry partners**: Working together to enhance prostate cancer screening technologies using nanotechnology. - **PanGIA Biotech and Canary Oncoceutics**: Launching the PanGIA Prostate Assay in India to enhance early prostate cancer detection. - **Macomics Ltd and Institute of Oncology Research**: Collaborating to explore macrophage-targeted therapies for prostate cancer using novel in vivo mouse models. - **Ontario Government and Novartis**: An agreement to publicly fund Pluvicto™, highlighting the need for innovative treatments for advanced prostate cancer. - **AngioDynamics and University College London Hospital**: Initiating a registry study to assess the long-term effects of the NanoKnife system for prostate cancer treatment. ### Innovations, Trends, and Initiatives - **COVID-19 Impact**: The pandemic has led to missed diagnoses and a rise in advanced prostate cancer cases, prompting a reevaluation of diagnostic protocols. - **Polygenic Risk Scores**: Research indicates that incorporating polygenic risk scores into screening could improve detection of clinically significant prostate cancers. - **Prostate Cancer Screening Guidelines**: PCF has published new guidelines for prostate cancer screening specifically for Black men to address health disparities. - **MyProstateScore 2.0 (MPS2)**: A urine test developed to detect high-grade prostate cancer, potentially reducing the need for invasive procedures. - **CAR T Cell Therapy**: Phase I trials indicate CAR T cell therapy targeting prostate stem cell antigen (PSCA) shows promise for advanced prostate cancer treatment. - **QP-Prostate CAD**: An FDA-cleared solution for prostate cancer lesion detection that utilizes advanced algorithms to improve diagnostic accuracy. - **177Lu-PSMA-617**: A treatment shown to extend survival in patients with metastatic castration-resistant prostate cancer. - **CAPFISH-3 Study**: A phase 2 study indicating that a diet high in omega-3 fatty acids may reduce prostate cancer cell growth. - **P-CARE Model**: A personalized prostate cancer risk assessment model developed from data of over 585,000 male participants, focusing on genetic scores and family history. - **Galleri Test**: A multi-cancer early detection test that effectively identifies aggressive prostate cancer while minimizing overdiagnosis. - **ClarityDX Prostate Test**: A new test being evaluated for its ability to accurately identify aggressive prostate cancer, potentially reducing unnecessary biopsies. - **Steam-Based Treatment**: A clinical trial exploring a steam-based method for treating intermediate-risk prostate cancer, aiming to reduce side effects. - **PSMA-PET Imaging**: Advanced imaging technique that significantly improves the accuracy of prostate cancer staging and treatment decisions. - **IsoPSA Test**: A novel prostate cancer screening test that improves detection accuracy by analyzing specific biomarkers in PSA. - **AI in Prostate Cancer Detection**: Mass General Brigham's AI model successfully identifies aggressive prostate lesions, aiding in treatment decisions. - **AR-ctDETECT Test**: A DNA sequencing test that differentiates between advanced prostate cancer patients with poor and favorable prognoses. ### Challenges and Concerns - **Aging Population**: The rising prevalence of prostate cancer in elderly males necessitates enhanced screening and management strategies. - **Treatment Resistance**: Prostate cancer often develops resistance to therapies, complicating treatment strategies and necessitating ongoing research. - **Overtreatment Issues**: Despite advancements, overtreatment of men with prostate cancer and limited life expectancy remains a concern, particularly for higher-risk cases. - **Rising Advanced Cases**: An alarming increase in advanced prostate cancer diagnoses, necessitating better education and communication regarding screenings. - **Screening Participation**: Low participation rates in prostate cancer screening among high-risk groups, leading to late-stage diagnoses and poorer outcomes. - **Long-term Risks of Treatment**: Studies indicate significant long-term risks of urinary and sexual complications for men treated for prostate cancer, emphasizing the need for informed decision-making. - **Health Disparities**: African American men face a significantly higher risk of prostate cancer, emphasizing the need for targeted awareness and treatment initiatives. - **Overtreatment**: The rise in aggressive treatment for intermediate and high-risk prostate cancer cases, particularly among men with limited life expectancy. - **Overdiagnosis Risks**: The challenge of balancing effective screening with the risk of overdiagnosing indolent cases of prostate cancer. - **Screening Awareness**: Misconceptions about prostate cancer screening deter men from seeking timely screenings, with many unaware of the importance of early detection. - **Treatment Complications**: Research indicates significant long-term risks of urinary and sexual complications from prostate cancer treatments, necessitating informed patient decisions. - **Screening Guidelines**: Current guidelines may overlook early-stage prostate cancer in transgender women due to lower PSA levels caused by hormone therapy. - **Late-Stage Diagnoses**: High rates of late-stage prostate cancer diagnoses in countries like India highlight the need for improved early detection systems. - **Access to Care**: Socioeconomic factors and genetic predispositions contribute to disparities in access to prostate cancer screening and treatment.